Overview

Changes in Cerebral Function in Treatment Naive HIV-1 Infected Subjects Commencing Either Boosted Atazanavir With Truvada or Boosted Darunavir With Maraviroc and Kivexa

Status:
Completed

Trial end date:
2015-10-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to compare two different combination anti-HIV therapies over 48 weeks and to assess if differences in improvement in the function of the brain are observed over this period. The study will compare anti-HIV therapy combinations which are currently in use. The patients will not have had any previous treatment for their HIV infection.

Phase:

Phase 4

Details

Lead Sponsor:

Imperial College London

Collaborator:

Pfizer

Treatments:

Atazanavir Sulfate
Darunavir
Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination
Maraviroc
Ritonavir